The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats

Pharmacotherapy

Volumn 17, Issue 2, 1997, Pages 342-347

  Johnston, Thomas P ^a   Palmer, Warren K ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIVER HOMOGENATE; LIVER MICROSOME; MALE; NONHUMAN; RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MICROSOMES, LIVER; POLOXALENE; PRAVASTATIN; RATS; RATS, SPRAGUE-DAWLEY; SURFACE-ACTIVE AGENTS;

EID: 0030894722     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kritchevsky D. Animal models for atherosclerotic research. In: Kritchevsky D, ed. Handbook of experimental pharmacology; hypolipidemic agents. New York: Springer-Verlag, 1975: 215-27.
2. Ness GC, Keller RK, Pendleton LC. Feedback regulation of hepatic 3-hydroxy-3-methylglutaryl-CoA reductase activity by dietary cholesterol is not due to altered mRNA levels. J Biol Chem 1991;266(23):14854-7.
3. Mori Y, Wada H, Nagano Y, Deguchi K, Kita T, Shirakawa S. Hypercoagulable state in the Watanabe heritable hyperlipidemic rabbit, an animal model for the progression of atherosclerosis: effect of probucol on coagulation. Thromb Haemost 1989;61:140-3.
4. Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL rabbit). Incidence and development of atherosclerosis and xanthoma. Atherosclerosis 1980;36:261-8.
5. Fantappie S, Crestani M, Bosisio E, et al. Plasma lipoproteins and cholesterol metabolism in spontaneously hyperlipidemic rats. Atherosclerosis 1989;76:163-71.
6. Wout ZG, Pec EA, Johnston TP. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J Parenteral Sci Technol 1992;46:192-200.
7. Schmolka IR. Poloxamers in the pharmaceutical industry. In: Tarcha PJ, ed. Polymers for controlled drug delivery. Boca Raton, FL: CRC Press, 1991:189-215.
8. Johnston TP, Miller SC. Toxicological evaluation of poloxamers for intramuscular use. J Parenteral Sci Technol 1985;39:83-8.
9. Pec EA, Wout ZG, Johnston TP. Biological activity of urease formulated in poloxamer 407 following intraperitoneal injection in the rat. J Pharm Sci 1992;81:626-30.
10. BASF Wyandotte Corp. Pluronic polyols: toxicity and irritation data. Parsippany, NJ: Author, 1978.
11. Porter JA, Carter BL, Johnston TP, Palmer WK. Effects of pravastatin on plasma lipid concentrations in poloxamer 407-induced hyperlipidemic rats. Pharmacotherapy 1995;15:92-8.
12. Nash VL, Johnston TP, Palmer WK. Effects of nicotinic acid on poloxamer-induced hyperlipidemia. Pharmacotherapy 1996;16:10-15.
13. Johnston TP, Palmer WK. Effect of poloxamer 407 on the activity of microsomal 3-hydroxy-3-methylglutaryl CoA reductase in rats. J Cardiovasc Pharm 1997 In press.
14. BASF Corp. Technical data bulletin on pluronic and tetronic surfactants. Parsippany, NJ: Author, 1989.
15. Ma PTS, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 1986;83:8370-4.
16. Shefer D, Salen G, Batta AK. Methods of assay. In: Sabine JR, Fears R, eds. Cholesterol 7-α-hydroxylase (7 α-monooxygenase). Boca Raton, FL: CRC Press, 1986:43-9.
17. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85.
18. Edwards PA, Lemongello D, Fogelman AM. Improved methods for the solubilization and assay of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Lipid Res 1979;20:40-6.
19. Segel IH. Enzyme kinetics: behavior and analysis of rapid equilibrium and steady state enzyme systems. New York: John Wiley & Sons, 1975:174.
20. Tsujita Y, Kuroda M, Shimada Y, et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibitor of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 1986;877:50-60.
21. Scott WA, Mahoney EM, Mosley ST. Mechanism of action and differential pharmacology of pravastatin, a hydrophilic and selective HMG-CoA reductase inhibitor. In: LaRosa JC, ed. New advances in the control of lipid metabolism: focus on pravastatin. London: Royal Society of Medicine Services, International Congress and Symposium Series, 1989:1-8.
22. Del Puppo M, Rauli S, Galli Kienle M. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl CoA reductase in rats by simvastatin and pravastatin. Lipids 1995;30:1057-61.
23. Fujioka T, Nara F, Tsujita Y, Fukushige J, Fukami M, Kuroda M. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim Biophys Acta 1995;1254:7-12.